Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Emerging biopharmaceutical company AlphaRx is to collaborate with Israeli biopharmaceutical company PharmaSeed to develop drugs from a new class of small molecules for the potential treatment of central nervous system disorders such as stroke and multiple sclerosis.
Subscribe to our email newsletter
Under the collaboration, AlphaRx will be responsible for the synthesis, characterization, formulation, analysis and production of this new class of compounds, which PharmaSeed will evaluate in stroke and multiple sclerosis models.
The companies said that they may create a joint venture for the subsequent commercialization of selected molecules arising out of the collaboration.
According to AlphaRx its lead compounds have shown significant immune system modulating properties, low toxicity, rapid onset and potent anti-inflammatory activity in preclinical studies conducted by the company.
PharmaSeed utilizes small animal neurological models, behavioral testing and preclinical neurotoxicological assays to establish proof-of-concept for the treatment of CNS diseases and to provide essential information about drug efficacy and safety.
“We are excited to work with PharmaSeed to build on complementary platforms that have the potential to develop therapeutic solutions for large unmet medical needs,” said Michael Lee, CEO of AlphaRx. “Based upon promising preclinical results, we are optimistic that the relationship with PharmaSeed will help the company advance our programs through clinical development.”